Skip to main content
. 2009 Feb 9;27(8):1268–1274. doi: 10.1200/JCO.2008.17.5984

Table 2.

PFS and OS Summary Statistics

Survival Data Treatment Arm
Erlotinib BCNU/TMZ
Median PFS, months 1.8 2.4
6-month PFS
    % 11.4 24.1
    95% CI* 4.6 to 21.5
1-year PFS, % 5.7 4.0
Median OS, months 7.7 7.3
6-month OS, % 57.6 58.5
1-year OS, % 21.9 26.7

Abbreviations: PFS, progression-free survival; OS, overall survival; BCNU, carmustine; TMZ, temozolomide.